Valuation: Beta Bionics, Inc.

Market Cap 719M 632M 587M 540M 1.01B 69.61B 1.03B 7.02B 2.74B 33.95B 2.7B 2.64B 118B P/E 2026 *
-7.23x
P/E 2027 * -7.24x
Enterprise Value 719M 632M 587M 540M 1.01B 69.61B 1.03B 7.02B 2.74B 33.95B 2.7B 2.64B 118B EV / Sales 2026 *
5.39x
EV / Sales 2027 * 4x
Free-Float
98.91%
Yield 2026 *
-
Yield 2027 * -
1 day-1.10%
1 week-4.56%
Current month+2.94%
1 month+18.00%
3 months+41.12%
6 months+1.07%
Current year-47.06%
1 week 15.53
Extreme 15.53
18.2
1 month 14.62
Extreme 14.62
18.2
Current year 8.8
Extreme 8.8
32.58
1 year 8.8
Extreme 8.8
32.71
3 years 8.8
Extreme 8.8
32.71
5 years 8.8
Extreme 8.8
32.71
10 years 8.8
Extreme 8.8
32.71
Manager TitleAgeSince
Chief Executive Officer 50 14/08/2022
Director of Finance/CFO 37 31/07/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 57 31/01/2020
Director/Board Member 50 14/08/2022
Director/Board Member 63 30/09/2024
Date Insider Type Main position Quantity % Market Cap.
29/06/26 Fiscal year

Chief Financial Officer

14,688 0.0330%
29/06/26 Fiscal year

Chief Financial Officer

14,688 0.0330%
24/06/26 Sell

Executive/Senior Manager

-1,258 0.0028%
Change 5-day change 1-year change 3-year change Capi.($)
-1.10%-4.56%+9.21% - 719M
+8.71%+5.36%+22.63%+1.80% 213B
+7.46%-6.10%-2.72%-24.77% 135B
-2.54%-17.48%-33.85%-1.38% 117B
+1.42%-2.33%-59.56%-18.02% 64.78B
-0.65%-4.58%+8.98%-9.45% 48.26B
-1.56%-3.21%-26.85%-33.72% 43.08B
+4.71%+2.67%+16.97%+9.50% 39.47B
+3.13%+1.12%+29.35%+32.45% 37.55B
+3.14%+3.47%+88.18%+3.34% 29.78B
Average +2.00%-3.49%+5.23%-4.47% 72.89B
Weighted average by Cap. +3.81%-4.90%+0.41%-6.20%

Financials

2026 *2027 *
Net sales 133M 117M 109M 100M 188M 12.91B 191M 1.3B 508M 6.3B 500M 490M 21.85B 180M 158M 147M 135M 253M 17.39B 258M 1.75B 684M 8.48B 674M 659M 29.42B
Net income -99.93M -87.89M -81.65M -75.09M -141M -9.68B -143M -976M -381M -4.72B -375M -367M -16.38B -99.35M -87.38M -81.17M -74.66M -140M -9.62B -143M -971M -379M -4.69B -373M -365M -16.28B
Net Debt - -
Logo Beta Bionics, Inc.
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
Employees
422
Date Price Change Volume
23/07/26 US$16.13 -1.10% 1,329,100
22/07/26 US$16.31 -7.43% 1,386,635
21/07/26 US$17.62 -1.12% 1,095,304
20/07/26 US$17.82 +3.07% 711,845
17/07/26 US$17.29 +2.31% 1,233,773
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
16.13USD
Average target price
19.80USD
Spread / Average Target
+22.75%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BBNX Stock